Please log in to determine if you are eligible to purchase PT Programs.

The correlation of cervicovaginal cytology (Pap test) findings with cervical biopsy results is a significant part of the cytopathology laboratory’s quality assurance program. By monitoring this correlation, the laboratory can identify and address potential problems requiring improvement, thereby ensuring better patient results. This Q-TRACKS study helps laboratories meet CAP Laboratory Accreditation Program Cytopathology Checklist statements CYP.01900, CYP.07543, and CYP.07600 on cytologic/histologic correlation, and The Joint Commission Standard QSA. 08.06.03: The cytology laboratory has a process to correlate cytologic interpretations with the corresponding histologic finding.


Quantify the correlation between the findings of cervicovaginal cytology and corresponding histologic material.

Data Collection

On a monthly basis, participants will record the number of true-positive, false-positive, and false-negative cytology-biopsy correlations. The false-negative correlations will be classified into four error categories: screening errors, interpretive errors, screening and interpretive errors, and adequacy determination errors. Participants will also record the biopsy diagnoses for Pap tests with an interpretation of atypical squamous cells (ASC-US and ASC-H) or atypical glandular cells (AGC). This monitor includes cervical biopsy specimens submitted to the laboratory that have a corresponding satisfactory or satisfactory but limited Pap test within three months of the biopsy.

Performance Indicators

  • Predictive value of positive cytology (%)
  • Sensitivity (%)
  • Screening/interpretation sensitivity (%)
  • Sampling sensitivity (%)
  • Percent positive for ASC-US interpretations
  • Percent positive for ASC-H interpretations
  • Percent positive for AGC interpretations

Shipping Schedule

  • Shipment A: December 5, 2022
  • Shipment B: March 13, 2023
  • Shipment C: June 12, 2023
  • Shipment D: September 11, 2023

Additional Information

Participants in this program receive:

  • User Guide
  • Templates and instructions for data collection
  • Quarterly reports that include fingerprint clusters, customer-defined groups, and all institution comparisons
  • Peer directory

Quality Management Tools activities meet the American Board of Pathology MOC Part IV Practice Performance Assessment requirements.

For Comprehensive Collection of Tools, see Quality Management Tools.

Select Q-PROBES and Q-TRACKS studies to support your quality improvement initiatives.
Anatomic Pathology
Clinical Pathology
Turnaround Time
Patient Safety
Transfusion Medicine
Chemistry/ Hematology
Customer Satisfaction
Non-Physician Care Team Satisfaction With Clinical Laboratory Services (QP231)
Technical Competency Assessment of Body Fluid Review (QPB10)
Technical Competency Assessment of Peripheral Blood Smears (QPC10/QPC25)
Technical Competency Assessment of Gram Stains (QPD10/QPD25)
Patient Identification Accuracy (QT1)
Blood Culture Contamination (QT2)
Laboratory Specimen Acceptability (QT3)
In-Date Blood Product Wastage (QT4)
Gynecologic Cytology Outcomes: Biopsy Correlation Performance (QT5)
Satisfaction with Outpatient Specimen Collection (QT7)
Stat Test Turnaround Time Outliers (QT8)
Critical Values Reporting (QT10)
Troponin Turnaround Times (QT15)
Corrected Results (QT16)
Outpatient Order Entry Errors (QT17)

*The CAP requires accredited laboratories to have a quality management plan that covers all areas of the laboratory and includes benchmarking key measures of laboratory performance (GEN.13806, GEN.20316, COM.04000). The Joint Commission requires accredited hospitals to regularly collect and analyze performance data (PI.01.01.01, PI.02.01.01). CLIA requires laboratories to monitor, assess, and correct problems identified in preanalytic, analytic, and postanalytic systems (§493.1249, §493.1289, §493.1299).